Skip to Content
image description
  • image description
  • image description
  • image description

Zdenka Ena Segota, MD

photo of Dr. Z. Ena Segota
Telephone: 
(954) 267-7700
Fax: 
(954) 267-7799
Specialty/Specialties: 
Hematology and Oncology
Holy Cross Medical Group: 
Yes

Office Hours
Mon-Fri 9:00am to 12:00pm, 1:00pm to 4:00pm

Click here to view Dr. Segota's Webisode.

Focus Areas
Breast, GYN, Lymphoma

Certifications
American Board of Internal Medicine
American Board of Internal Medicine - Hematology
American Board of Internal Medicine - Medical Oncology

Residency / Fellowship
Fellowship, Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH (2003-2006) 

Research Fellowship, Experimental Therapeutics, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH (2002-2003)
 
Internship/Residency, Department of Internal Medicine, Huron Hospital-Cleveland Clinic Health System, Cleveland, OH (1999-2002)

Higher Education
University of Zagreb School of Medicine, Zagreb, Croatia M.D. (1995)

Professional Associations
American Board of Internal Medicine
American Society of Clinical Oncology
American Society of Hematology
Broward Medical Society
Cancer Committee Holy Cross Hospital
Electronic Medical Records Committee

Awards
Glaxo-Smith Kline Travel Award GSK Conference, Miami, FL (4/2003)

Annual Huron Research Competition Award (6/2002) “Angiogenesis in Waldenstrom macroglobulinemia—correlation with treatment and prognostic factors”.

Outstanding Presenter-Honor Award, 2002 Annual Associates Meeting, ACP-ASIM Ohio Chapter

Research/ Publications

Abstracts
Segota E, Soares HP,Kumar A, Bassler D, Guyatt GH, Djulbegovic B. Randomized Clinical Trials in Oncology Stopped Early for Benefit (RCTSEB). J Clin Oncol, 2006 ASCO Annual Meeting Proceedings. Vol 24, No 18S(June Supplement), 2006:6039

Wongchaowart N, Segota E, Hsi E, Jin T, Rybicki L, Pohlman B. Immunohistochemical Expression of CD10, BCL6, and MUM1 in primary nodal diffuse large B-cell lymphoma: MUM1 Expression alone (but not germinal center B-cell immunophenotype) is an independent prognostic factor. United States and Canadian Academy of Pathology conference. Data will be added to Stanford and Florida data for final publication in a larger study.

Segota E, Shaheen P, Hsi E, Kalaycio M. Splenectomy in splenic marginal zone lymphoma. Presented at ASH Annual Meeting 12/2005 (Abstract 590-III).

Segota E, Pohlman B, Jin T, Kuczkowski E, Kalaycio M, Sobecks R, Andresen S, Bolwell B. High dose chemotherapy with autologous stem cell transplant (ASCT) for mantle cell lymphoma (MCL). J Clin Oncol, 2005 ASCO Annual Meeting Proceedings. Vol 23(16), No 602S (June 1 Supplement), 2005:6668

Segota E, Misbah SA, Crowe J, Tubbs R, Casey G, Elson P, Wacker B, Budd GT.    Absolute neutrophil count pattern (ANC) with accelerated dose-intensified epirubicin chemotherapy and pegfilgrastim support. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings. Vol 22, No 14S (July 15 Supplement), 2004:8229

Misbah SA, Segota E, Elson P, Bukowski R. Frequency and survival impact of osseous metastases in patients with untreated renal cell carcinoma. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings. Vol 22, No 14S (July 15 Supplement), 2004:4631
    
Segota E, Mekhail T, Olencki T, Hutson T, Wacker B, Cowen D, Budd GT, Dreicer R, Elson P, Bukowski R. Phase II trial of capecitabine and rHuIFN-2a in patients with metastatic renal cell carcinoma. J Clin Oncol, Proc Am Soc Clin Oncol 2003; 22:417a (A1674)

Segota E, Huitzil D, Olencki T, Finke JH. Analysis of clinical and pathological characteristics in 7 patients with thin metastatic melanoma. FASEB JOURNAL 17(4): A267-A268 Part 1 Suppl.S Mar 14, 2003 (Presented at Experimental Biology Conference, San Diego 2003).

Motallebi M, Segota E, Ravakhah K. Rare tumor of the ovary with even rarer site of metastasis. Proceedings ACP-ASIM Ohio Chapter Scientific Meeting in 2002

Kocharian N, Segota E, Ashraf S. Severe pancytopenia in a patient with pernicious anemia at the time of influenza infection. Proceedings ACP-ASIM Ohio Chapter Scientific Meeting 2002

Segota E, Ravakhah K. Is there an entity in between Hodgkin’s and Non-Hodgkin’s lymphoma?  Proceedings Experimental Biology Conference, New Orleans 2002

Segota E, Miller S, Brateanu A. Breast necrosis from calcific uremic arteriolopathy: A case report.  Proceedings ACP-ASIM Ohio Chapter Meeting 2001

Segota E, Solti M, Lagman D, Shekar R. Clostridium cadaveris
Bacteremia. Proceedings ACP-ASIM Ohio Chapter Scientific Meeting 2000

Manuscripts
Segota E, Mekhail T, Olencki T, Hutson T, Wacker B, Cowen D, Budd GT, Dreicer R, Elson P, Bukowski R. Phase II trial of capecitabine and rHuIFN-2a in patients with metastatic renal cell carcinoma.  Urol Oncol. 2007 Feb;25(1);46-52.

Tamaskar I, Segota E, Kalaycio M, Maciejewski J. The clinical picture. A woman with aplastic anemia and a rash. Cleve Clin J Med. 2006 Dec;73(12):1088-90.

Segota E, Adelstein D, Mekhail T. A woman with headache and blurred vision.
Cleve Clin J Med. 2005 Oct;72(10):848-851.

Segota E, Bukowski RM. The promise of targeted therapy: cancer drugs become more specific.  Cleve Clin J Med. 2004 Jul;71(7):551-60.

Rudan I, Rudan N, Basic N, Basic V, Rudan D, Jambrisak Z. Differences between male and female breast cancer. III. Prognostic features. Acta med. Croatica, 51 (1997), pp. 135-141.

Location

4725 N. Federal Highway, Cancer Center
Fort Lauderdale, FL 33308

HCMG Practice Locations

Map

Women's Center Physicians

Women's Center Physicians

Practices

image description

New Primary Care Physician

David Dunhill MD Internal Medicine